Literature DB >> 21236668

Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis.

Alejandra Yep1, Roderick J Sorenson, Michael R Wilson, H D Hollis Showalter, Scott D Larsen, Paul R Keller, Ronald W Woodard.   

Abstract

We explored the D-arabinose 5-phosphate isomerase (KdsD, E.C. 5.3.1.13) from Francisella tularensis, a highly infectious gram-negative pathogen that has raised concern as a potential bioweapon, as a target for the development of novel chemotherapeutics. F. tularensis KdsD was expressed in Escherichia coli from a synthetic gene, purified, and characterized. A group of hydroxamates designed to be mimics of the putative enediol intermediate in the enzyme's catalytic mechanism were prepared and tested as inhibitors of F. tularensis KdsD. The best inhibitor, which has an IC(50) of 7 μM, is the most potent KdsD inhibitor reported to date.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21236668     DOI: 10.1016/j.bmcl.2010.12.066

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Structural analysis of arabinose-5-phosphate isomerase from Bacteroides fragilis and functional implications.

Authors:  Hsiu Ju Chiu; Joanna C Grant; Carol L Farr; Lukasz Jaroszewski; Mark W Knuth; Mitchell D Miller; Marc André Elsliger; Ashley M Deacon; Adam Godzik; Scott A Lesley; Ian A Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2014-09-27

2.  A spontaneous mutation in kdsD, a biosynthesis gene for 3 Deoxy-D-manno-Octulosonic Acid, occurred in a ciprofloxacin resistant strain of Francisella tularensis and caused a high level of attenuation in murine models of tularemia.

Authors:  Taylor Chance; Jennifer Chua; Ronald G Toothman; Jason T Ladner; Jonathan E Nuss; Jo Lynne Raymond; Fabrice V Biot; Samandra Demons; Lynda Miller; Stephanie Halasohoris; Sherry Mou; Galina Koroleva; Sean Lovett; Gustavo Palacios; Nicholas J Vietri; Patricia L Worsham; Christopher K Cote; Todd M Kijek; Joel A Bozue
Journal:  PLoS One       Date:  2017-03-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.